Form 4: Vaxcyte Director Lukatch Exercises Stock Options, Reports Beneficial Ownership Changes
SEC Form 4 Filing
Director Heath Lukatch exercised stock options at Vaxcyte, Inc. on April 8, 2025, resulting in changes to his beneficial ownership of company stock.
Summary
- On April 8, 2025, Heath Lukatch, a director of Vaxcyte, Inc., executed transactions involving stock options.
- Lukatch exercised options to acquire 6,000 shares of common stock at a price of $16 per share.
- He also exercised options to acquire 1,000 shares of common stock at a price of $21.49 per share.
- Following these transactions, Lukatch directly owns 14,175 shares of Vaxcyte common stock.
- He also holds options to purchase 14,000 additional shares.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option exercises, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 04/08/2025 | Date of earliest transaction (exercise of stock options). |
| 04/10/2025 | Date of signature on the Form 4 filing. |
| 06/10/2030 | Expiration date of one set of stock options. |
| 06/01/2031 | Expiration date of another set of stock options. |
Keywords
Vaxcyte, PCVX, Director, Stock Options, Beneficial Ownership, Form 4, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.